Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA

Bitget2026/09/30 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pierre Fabre Pharmaceuticals resubmitted the tabelecleucel BLA to the FDA for relapsed/refractory EBV+ PTLD in SOT or HCT patients.
Atara Biotherapeutics expects to provide a revised PDUFA date once the FDA sets the review timeline.
FDA approval would trigger a USD 31 million milestone payment to Atara under its Pierre Fabre commercialization deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930946884) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA

You may also like

Crypto prices